• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CARBAMAZEPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CARBAMAZEPINE chembl:CHEMBL108 ApprovedImmunotherapy

    Alternate Names:

    EPITOL
    EPIMAZ
    TEGRETOL PROLONGED RELEASE
    TEGRETOL-XR
    TIMONIL 200 RET
    CARBAGEN SR
    EQUETRO
    TERIL
    NSC-169864
    SIRTAL RET
    TERIL RET
    G-32883
    GEIGY 32883
    ARBIL MR
    CARBATROL
    CARNEXIV
    TIMONIL 400 RET
    TEGRETOL CHEWTAB
    EPIMAZ RET
    TEGRETOL XR
    CARBAMAZEPINE
    TEGRETOL
    5-CARBAMOYL-5H-DIBENZ[B,F]AZEPINE
    CBZ
    5-CARBAMOYL-5H-DIBENZO(B,F)AZEPINE
    5-CARBAMYL-5H-DIBENZO(B,F)AZEPINE
    5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
    5-CARBAMOYL-5H-DIBENZ(B,F)AZEPINE
    CARBAMAZEPEN
    CARBAMAZEPINUM
    CALEPSIN
    TEGRETOL®
    CARBAMAZEPINA
    CARBAMAZEPIN
    CARBAMAZÉPINE
    TEG111
    pubchem.compound:2554
    chemidplus:298-46-4
    chembl:CHEMBL108
    rxcui:2002
    drugbank:00564

    Drug Info:

    Year of Approval 1968
    Drug Class anticonvulsants
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of bipolar disorder
    (5 More Sources)

    Publications:

    Djordjevic N et al., 2016, CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy., Eur J Clin Pharmacol
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Yang et al., 2010, Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels., Anesthesiology
    Lipkind et al., 2010, Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore., Mol. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Yang et al., 2002, Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker., Mol. Pharmacol.
    Himmerich et al., 2005, Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium., Psychopharmacology (Berl.)
    Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
    Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics
    Hung SI et al., 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions., Pharmacogenet Genomics
    Zhou BT et al., 2012, Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up., CNS Neurosci Ther
    He XJ et al., 2013, Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China., Pharmacol Rep
    Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
    Pirmohamed M et al., 2001, TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients., Neurology
    Puranik YG et al., 2013, Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy., Pharmacogenomics
    Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
    Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
    Rädisch S et al., 2014, A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine., Pharmacogenomics J
    Sporis D et al., 2013, Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy., Coll Antropol
    Qu J et al., 2012, ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients., CNS Neurosci Ther
    Hilger E et al., 2012, Lack of association between ABCC2 gene variants and treatment response in epilepsy., Pharmacogenomics
    Hung CC et al., 2012, Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization., Pharmacogenomics
    Ufer M et al., 2011, Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy., Pharmacogenet Genomics
    Kwan P et al., 2011, Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy., Pharmacogenomics
    Kim WJ et al., 2010, A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy., Pharmacogenet Genomics
    Alfirevic et al., 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity., Pharmacogenomics
    Kim et al., 2007, A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy., Epilepsy Behav
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Gjestad C et al., 2016, 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?, Br J Clin Pharmacol
    Wang P et al., 2015, Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy., Epilepsy Res
    Zhu X et al., 2014, Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy., Pharmacogenomics
    Li LJ et al., 2013, Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese., Epilepsy Res
    Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
    Saruwatari J et al., 2014, Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction., Pharmacogenet Genomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Bonuccelli et al., 1985, Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects., Clin Neuropharmacol
    Isojärvi et al., Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy., Epilepsia
    Alfirevic A et al., 2006, Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster., Pharmacogenet Genomics
    Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Tutor-Crespo et al., [A study of some indirect biochemical markers in the evaluation of enzymatic induction caused by antiepileptic drugs]., Rev Neurol
    Shen C et al., 2017, Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy., Seizure
    Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
    Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
    Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
    Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
    Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
    Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
    Daci A et al., 2015, Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients., PLoS One
    Ma CL et al., 2015, Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy., Pharmacogenomics
    Zhou BT et al., 2012, Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population., Clin Exp Pharmacol Physiol
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
    Manna I et al., 2011, A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy., Epilepsia
    Schlachter K et al., 2009, A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures., Neurology
    Rogawski et al., 2004, The neurobiology of antiepileptic drugs., Nat. Rev. Neurosci.
    Makmor-Bakry M et al., 2009, Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing., Clin Neuropharmacol
    Nakajima Y et al., 2005, Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients., Eur J Clin Pharmacol
  • CARBAMAZEPINE   HSPA1L

    Interaction Score: 2.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16538175


    Sources:
    PharmGKB

  • CARBAMAZEPINE   HSPA1A

    Interaction Score: 2.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16538175


    Sources:
    PharmGKB

  • CARBAMAZEPINE   BAG6

    Interaction Score: 2.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16538176


    Sources:
    PharmGKB

  • CARBAMAZEPINE   RALBP1

    Interaction Score: 1.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21738081


    Sources:
    PharmGKB

  • CARBAMAZEPINE   EPHX1

    Interaction Score: 1.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26314341 25495409 22188362 19620853 15692831


    Sources:
    PharmGKB

  • CARBAMAZEPINE   PRRC2A

    Interaction Score: 0.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16538176


    Sources:
    PharmGKB

  • CARBAMAZEPINE   LTA

    Interaction Score: 0.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11294926


    Sources:
    PharmGKB

  • CARBAMAZEPINE   TNFRSF1B

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15565432


    Sources:
    NCI

  • CARBAMAZEPINE   CYP2A6

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • CARBAMAZEPINE   SCN1A

    Interaction Score: 0.38

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    28753467 26555147 26314341 25155934 23859570 22591328 22292851 22188362 21747585 21561445 19289736 12391287 20643904 15208697 20526191


    Sources:
    ChemblInteractions PharmGKB

  • CARBAMAZEPINE   POU5F1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CARBAMAZEPINE   ABCC2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25155934 24567120 23697249 23252947 22630058 22256867 22188362 21799461 21738081 21449672 20216337


    Sources:
    PharmGKB

  • CARBAMAZEPINE   HNF4A

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28837897 24384557


    Sources:
    PharmGKB

  • CARBAMAZEPINE   HLA-DQB1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24399721


    Sources:
    PharmGKB

  • CARBAMAZEPINE   NR1I3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21738081


    Sources:
    PharmGKB

  • CARBAMAZEPINE   CYP1A1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26951882 21121773


    Sources:
    PharmGKB

  • CARBAMAZEPINE   HLA-B

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16981842


    Sources:
    NCI FDA

  • CARBAMAZEPINE   GGT1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12402220


    Sources:
    NCI

  • CARBAMAZEPINE   CYP2B6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977870 21738081 17638512


    Sources:
    NCI PharmGKB

  • CARBAMAZEPINE   HLA-DRB1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24399721 23830818


    Sources:
    PharmGKB

  • CARBAMAZEPINE   UGT2B7

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21738081


    Sources:
    PharmGKB

  • CARBAMAZEPINE   SCN5A

    Interaction Score: 0.13

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Trial Name SPD 417, carbamazepine,Equetro, Carbatrol

    PMIDs:
    20526191 20643904 17016423 17139284 12391287


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • CARBAMAZEPINE   PRL

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3924400 3191895


    Sources:
    NCI

  • CARBAMAZEPINE   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034 26421491 25495409 24384557 23252947 21738081 18695978


    Sources:
    NCI PharmGKB

  • CARBAMAZEPINE   BGLAP

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17224308


    Sources:
    NCI

  • CARBAMAZEPINE   SCN2A

    Interaction Score: 0.11

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    25155934 23859570 18784617


    Sources:
    ChemblInteractions PharmGKB

  • CARBAMAZEPINE   MTHFR

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12083967


    Sources:
    PharmGKB

  • CARBAMAZEPINE   CYP2C8

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21738081


    Sources:
    PharmGKB

  • CARBAMAZEPINE   HLA-A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • CARBAMAZEPINE   TNF

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11294926 15565432


    Sources:
    NCI PharmGKB

  • CARBAMAZEPINE   NR1I2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    23252947 21738081 14977870


    Sources:
    PharmGKB

  • CARBAMAZEPINE   GABRA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22591328


    Sources:
    PharmGKB

  • CARBAMAZEPINE   SCN7A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   SCN8A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   SCN3A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   SCN11A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   SCN4A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   SCN9A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   SCN10A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARBAMAZEPINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528 26574235 26421491 25495409 23252947 21738081 22931300


    Sources:
    DTC PharmGKB

  • CARBAMAZEPINE   NR3C1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBAMAZEPINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26762380 22931300


    Sources:
    DTC PharmGKB

  • CARBAMAZEPINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • CARBAMAZEPINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CARBAMAZEPINE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CARBAMAZEPINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CARBAMAZEPINE

    • Version: 01-August-2011

    Alternate Names:
    CARBAMAZEPINE Primary Drug Name

    Drug Info:
    Drug Class anticonvulsants
    Year of Approval 1968

    Publications:

  • TdgClinicalTrial: CARBAMAZEPINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of bipolar disorder
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: CARBAMAZEPINE

    • Version: 14-September-2017

    Alternate Names:
    C341 NCI drug code

    Drug Info:

    Publications:
    Kim et al., 2007, A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy., Epilepsy Behav
    Isojärvi et al., Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy., Epilepsia
    Bonuccelli et al., 1985, Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects., Clin Neuropharmacol

  • DTC: CARBAMAZEPINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL108 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: carbamazepine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Djordjevic N et al., 2016, CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy., Eur J Clin Pharmacol
    Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
    Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics

  • TTD: Carbamazepine

    • Version: 2020.06.01

    Alternate Names:
    D04MSM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL108

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL108

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Carbamazepine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21